In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Context Therapeutics (CNTX – Research Report), with a price target of $6.00. The company’s shares closed yesterday at $1.38.
According to TipRanks, Bodnar is an analyst with an average return of -13.8% and a 24.07% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as SQZ Biotechnologies, Context Therapeutics, and Ventyx Biosciences.
Context Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $6.00.
See today’s best-performing stocks on TipRanks >>
Based on Context Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $3.85 million. In comparison, last year the company had a GAAP net loss of $1.44 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer.
Read More on CNTX:
- Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors
- Context nominated CTIM-76 as candidate to target Claudin 6-positive cancers
- Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium
